XNAS
ECOR
Market cap87mUSD
Oct 08, Last price
9.51USD
1D
-2.16%
1Q
44.20%
IPO
-96.59%
Name
electroCore, Inc.
Chart & performance
P/E
—
P/S
2.68
EPS
—
Div yield, %
—
Shrs. gr., 5y
26.68%
Rev. gr., 5y
55.74%
Revenues
32m
+27.20%
Net income
-14m
L+17.50%
CFO
-8m
L+17.83%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Key people
Steve Mendez
Co-Founder, Chief Technical Officer · since 2016
Eric J. Liebler
Senior Vice President - Neurology
Ardelle Ferris
Vice President-Market Access
Mike Romaniw
Vice President, Quality Assurance & Regulatory Affairs
Bruce J. Simon
Vice President,Research
Chief Medical Officer · since 2019
Chairman of the Board · since 2020
Nick Colucci
Director
Joseph P Errico
Chairman of the Board, Co-Founder, Principal Investor and Chief Science & Strategy Officer · since 2016
Thomas J. Errico
Co-Founder, Board Member and Principal Investor
Chief Executive Officer, Director · since 2019
Thomas M. Patton
Independent Director · since 2020
Headquarters & legal address
C/O Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
US
251 Little Falls Drive
Wilmington, DE 19808
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||